Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

This trial is testing whether continuous glucose monitoring (CGM) — a small wearable sensor that tracks blood sugar levels throughout the day and night — can be used in the postpartum period (after delivery) to identify women with gestational diabetes who are at high risk of developing type 2 diabetes later in life. Gestational diabetes often resolves after delivery, but these women remain at elevated risk for permanent diabetes. **You may be eligible if:** - You receive prenatal care at UCLA Health - You are planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica - You have been diagnosed with gestational diabetes (confirmed by a 2-step glucose test) - You are 18 years of age or older **You may NOT be eligible if:** - You had diabetes (Type 1 or Type 2) before your pregnancy - You are carrying multiple babies (twins, triplets, etc.) - You had a serious complication after delivery such as severe postpartum bleeding or were admitted to the ICU - You have a known allergy to medical-grade adhesive - You are scheduled for certain imaging tests (MRI, CT scan) during the trial period - You are currently taking metformin, steroids, or certain medications affecting blood sugar Talk to your doctor to see if this trial is right for you.